S

Supernus Pharmaceuticals
D

SUPN

33.060
USD
-1.53
(-4.42%)
مغلق
حجم التداول
38,548
الربح لكل سهم
1
العائد الربحي
-
P/E
31
حجم السوق
1,825,549,165
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    ALNY
    ALNY
    -0.480
    (-0.19%)
    250.450 USD
    A
    AVDL
    -0.05500
    (-0.65%)
    8.41000 USD
    B
    BPMC
    -2.080
    (-2.20%)
    92.280 USD
    ILMN
    ILMN
    -3.080
    (-3.17%)
    94.180 USD
    I
    IONS
    -0.365
    (-1.12%)
    32.310 USD
    N
    NBIX
    4.630
    (3.99%)
    120.710 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: Supernus Pharmaceuticals

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia inPD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.